Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group

Oscar Arrieta*, Andrés F. Cardona, Luis Lara-Mejía, David Heredia, Feliciano Barrón, Zyanya Lucia Zatarain-Barrón, Francisco Lozano, Vladmir Cordeiro de Lima, Federico Maldonado, Francisco Corona-Cruz, Maritza Ramos, Luis Cabrera, Claudio Martin, Luis Corrales, Mauricio Cuello, Marisol Arroyo-Hernández, Enrique Aman, Ludwing Bacon, Renata Baez, Sergio BenitezAntonio Botero, Mauricio Burotto, Christian Caglevic, Gustavo Ferraris, Helano Freitas, Diego Lucas Kaen, Sebastián Lamot, Gustavo Lyons, Luis Mas, Andrea Mata, Clarissa Mathias, Alvaro Muñoz, Ana Karina Patane, George Oblitas, Luis Pino, Luis E. Raez, Jordi Remon, Leonardo Rojas, Christian Rolfo, Alejandro Ruiz-Patiño, Suraj Samtani, Lucia Viola, Santiago Viteri, Rafael Rosell

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

The world currently faces a pandemic due to SARS-CoV-2. Relevant information has emerged regarding the higher risk of poor outcomes in lung cancer patients. As such, lung cancer patients must be prioritized in terms of prevention, detection and treatment. On May 7th, 45 experts in thoracic cancers from 11 different countries were invited to participate. A core panel of experts regarding thoracic oncology care amidst the pandemic gathered virtually, and a total of 60 initial recommendations were drafted based on available evidence, 2 questions were deleted due to conflicting evidence. By May 16th, 44 experts had agreed to participate, and voted on each of the 58 recommendation using a Delphi panel on a live voting event. Consensus was reached regarding the recommendations (>66 % strongly agree/agree) for 56 questions. Strong consensus (>80 % strongly agree/agree) was reached for 44 questions. Patients with lung cancer represent a particularly vulnerable population during this time. Special care must be taken to maintain treatment while avoiding exposure.

Original languageEnglish
Article number103033
JournalCritical Reviews in Oncology/Hematology
Volume153
DOIs
StatePublished - Sep 2020

Bibliographical note

Funding Information:
Dr. Andrés F. Cardona: reports grants from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb and The Foundation for Clinical and Applied Cancer Research – FICMAC., other from Pfizer, Boehringer Ingelheim, Astra Zeneca, MSD, BMS, Celldex, Roche, personal fees from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly and Foundation for Clinical and Applied Cancer Research – FICMAC, outside the submitted work.

Publisher Copyright:
© 2020 Elsevier B.V.

Keywords

  • COVID-19
  • Health systems
  • Lung cancer
  • Personal protective equipment
  • Recommendations
  • Thoracic oncology

Fingerprint

Dive into the research topics of 'Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group'. Together they form a unique fingerprint.

Cite this